PPBT (Purple Biotech) 12-1 Month Momentum %: -72.81% (As of Sep. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PPBT Purple Biotech Ltd PPBT
21 GF Score
Price $1.76
! 2 Warning Signs
View Full Analysis

What is Purple Biotech 12-1 Month Momentum %?

Purple Biotech PPBT -2.82% 21 12-1 Month Momentum % is -72.81% as of Sep. 12, 2026. GuruFocus rates PPBT with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 1,357 Biotechnology companies, Purple Biotech ranks better than 59.1% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-12), Purple Biotech's 12-1 Month Momentum % is -72.81%.

The industry rank for Purple Biotech's 12-1 Month Momentum % or its related term are showing as below:

PPBT's 12-1 Month Momentum % is ranked better than
59.1% of 1357 companies
in the Biotechnology industry
Industry Median: -19.89 vs PPBT: -72.81

Purple Biotech  (NAS:PPBT) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Purple Biotech 12-1 Month Momentum % Related Terms

PPBT vs VRTX, REGN, MRNA: 12-1 Month Momentum % Comparison

For the Biotechnology subindustry, Purple Biotech's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Purple Biotech 12-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Purple Biotech's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Purple Biotech's 12-1 Month Momentum % falls into.


PPBT
21GF Score
Purple Biotech Ltd PPBT
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Purple Biotech  (NAS:PPBT) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of -72.81% mean?
Purple Biotech (PPBT) has a 12-1 Month Momentum % of -72.81% as of Sep. 12, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Purple Biotech and its competitors. According to the industry distribution chart, Purple Biotech ranks #555 out of 1357 companies in the Biotechnology industry, placing it in the top 40.9%.
Is Purple Biotech's 12-1 Month Momentum % too high?
Purple Biotech's current 12-1 Month Momentum % is -72.81%. Based on the distribution chart, Purple Biotech ranks #555 out of 1357 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Purple Biotech has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Purple Biotech's 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Purple Biotech ranks #555 out of 1357 companies for 12-1 Month Momentum %. This puts Purple Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Purple Biotech and its competitors. Purple Biotech's current 12-1 Month Momentum % is -72.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Purple Biotech stock overvalued right now?
Purple Biotech (PPBT) has a current 12-1 Month Momentum % of -72.81%. The current 12-1 Month Momentum % is -72.81%. Purple Biotech's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Purple Biotech (PPBT), the current 12-1 Month Momentum % is -72.81% as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Purple Biotech Business Description

Other Exchanges PPBT:Israel
Address 4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
21GF Score

Get the complete analysis for PPBT

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.76
Price